RxDoctor Payments Data

Ravindra Majeti

Hematology · Stanford, CANPI 1326195447

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $56,107 of the $58,188 with a category attached, or 96.4%. Coherus Oncology, Inc. accounts for 77.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $22,500 and has fallen 67.2% since, to $7,370 in 2025.

$58,188in general payments, 2019–2025

Across 15 payments — averaging $3879.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coherus Oncology, Inc.$45K
  • E.r. Squibb & Sons, L.L.C.$7K
  • F. Hoffmann-la Roche AG$6K
  • Astellas Pharma US Inc$221
  • Takeda Pharmaceuticals U.S.A., Inc.$13
$708,465in research payments, 2019–2025

Across 2 payments — averaging $354,233 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$708K

What the payments were for

  • Consulting fees$56,10796%
  • Travel & lodging$1,4422%
  • Food & beverage$6391%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,188 in reported general payments places this provider in the 75th percentile of 178 hematology providers in California.

See all hematology providers in California

Other hematology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →